Nippon Chemiphar saw its generics sales slide down by 9.7% year-on-year to ¥12.28bn ($118m) in its financial first half ended 30 September 2020, compared to ¥13.61bn reported in the prior-year period, mainly due to National Health Insurance drug price revisions made in October 2019 and again in April 2020, as well as the impact of the coronavirus pandemic. In its non-pharmaceutical “other” segment too, Nippon Chemiphar saw its sales drop by 25.3% YoY as “the COVID-19 pandemic caused delays related to contracted testing.”
In March 2020, Nippon Chemiphar had reported that its operating profit more than halved since it was “unable to compensate...







